CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%

All Clinical Trials for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000468 ↗	Myocardial Infarction Triage and Intervention Project (MITI)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1988-04-01	To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00000468 ↗	Myocardial Infarction Triage and Intervention Project (MITI)	Completed	University of Washington	Phase 3	1988-04-01	To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00182143 ↗	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	Australian and New Zealand Intensive Care Society Clinical Trials Group	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	Canadian Critical Care Trials Group	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	Canadian Institutes of Health Research (CIHR)	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	McMaster University	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00203580 ↗	Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)	Completed	Canadian Institutes of Health Research (CIHR)	Phase 4	1994-12-01	The purpose of this study is to assess the long-term treatment of patients with proximal venous thrombosis through the administration of subcutaneous low-molecular-weight heparin (tinzaparin sodium) versus the standard care use of intravenous heparin followed by oral warfarin sodium.

Clinical Trial Conditions for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%

Condition Name

Condition Name for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%
Intervention	Trials
Myocardial Infarction	4
Healthy	4
Covid19	4
Thrombosis	4

Condition MeSH

Condition MeSH for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%
Intervention	Trials
Thrombosis	13
Acute Kidney Injury	7
Venous Thrombosis	7
COVID-19	6

Clinical Trial Locations for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%

Trials by Country

Trials by Country for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%
Location	Trials
United States	44
China	17
Canada	14
Brazil	12
Spain	11

Trials by US State

Trials by US State for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%
Location	Trials
California	7
New York	5
Texas	4
Ohio	3
Pennsylvania	2

Clinical Trial Progress for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%

Clinical Trial Phase

Clinical Trial Phase for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%
Clinical Trial Phase	Trials
Completed	48
Unknown status	13
Withdrawn	10

Clinical Trial Sponsors for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%

Sponsor Name

Sponsor Name for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%
Sponsor	Trials
Ain Shams University	5
GlaxoSmithKline	5
Azidus Brasil	4

Sponsor Type

Sponsor Type for Heparin Sodium 10,000 Units In Sodium Chloride 0.45%
Sponsor	Trials
Other	152
Industry	36
NIH	5

Clinical Trials Update, Market Analysis, and Projection for Heparin Sodium 10,000 Units in Sodium Chloride 0.45%

Last updated: October 30, 2025

Introduction

Heparin Sodium 10,000 Units in Sodium Chloride 0.45% is a widely used anticoagulant, primarily indicated for prophylaxis and treatment of thromboembolic disorders. Its clinical utility spans multiple medical settings, including cardiovascular surgeries, ongoing management of deep vein thrombosis (DVT), pulmonary embolism (PE), and during hemodialysis. Despite its long history of use, recent advances in anticoagulant therapy and evolving regulatory landscapes necessitate continuous monitoring of its clinical trials, market potential, and future projections. This article synthesizes current updates in clinical research, markets, and forecasts valuable insights for stakeholders.

---

Clinical Trials Update

Recent Clinical Research and Trials

While the majority of heparin's therapeutic indications are well established, recent clinical investigations have focused on optimizing dosing strategies, enhancing safety profiles, and exploring novel delivery mechanisms.

• Dosing Optimization and Safety:
  Ongoing trials aim to refine dosage protocols to balance efficacy with bleeding risks. For example, a phase IV study in 2022 examined low-dose heparin's efficacy in dialysis patients, demonstrating that tailored dosing reduces bleeding complications without compromising anticoagulation efficacy [1].

• Novel Delivery Systems:
  New formulations, such as controlled-release heparin patches and liposomal encapsulation, are under preclinical stages to improve tissue targeting and reduce systemic side effects. A 2021 pilot study investigated a liposomal heparin formulation that exhibited sustained anticoagulant activity in vivo [2].

• Comparative Effectiveness:
  Several trials compare heparin with newer anticoagulants, such as direct oral anticoagulants (DOACs). The HEPAR-DOAC study, ongoing as of 2023, compares low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) against DOACs in post-orthopedic surgery, offering insights into safety profiles and cost-effectiveness [3].

Regulatory and Approval Status

Heparin products generally face minimal regulatory hurdles due to their long-standing approval status. However, specific formulations, particularly those with modified delivery methods or molecular structures, require extensive clinical validation. The FDA has maintained a watchful stance, emphasizing safety monitoring for bleeding risks, particularly in vulnerable populations like pregnant women and neonates.

---

Market Analysis

Market Dynamics

The global heparin market is driven by increasing prevalence of cardiovascular diseases, expansion of hemodialysis services, and rising surgical procedures needing anticoagulants. According to a recent report, the global heparin market was valued at approximately USD 2.5 billion in 2022 and is projected to reach USD 3.8 billion by 2030, growing at a CAGR of around 5.0% [4].

Key Market Drivers:

• Cardiovascular Disease Incidence:
  The growing burden of atrial fibrillation, myocardial infarction, and venous thromboembolism maintains high demand.

• Expanding Surgical Procedures:
  Increased usage in coronary artery bypass grafting (CABG), prosthetic valve surgeries, and dialysis contributes to sustained market growth.

• Developing Countries:
  Rising healthcare infrastructure investments in Asia-Pacific and Latin America open new opportunities for distributors and local manufacturers.

Competitive Landscape

Major players include Pfizer (marketed as unfractionated heparin and low-molecular-weight versions), Leo Pharma, and CP Pharm. The market exhibits high consolidation, with Pfizer, Novartis, and other multinationals controlling significant shares. Entry barriers remain high due to manufacturing complexities and stringent regulatory standards.

Challenges and Risks

• Safety Concerns:
  Bleeding complications and heparin-induced thrombocytopenia (HIT) pose challenges, leading to some shifts towards alternative anticoagulants.

• Regulatory Scrutiny:
  Increasing global regulation demands, including quality control of heparin sources (notoriously linked to contamination episodes in 2008), necessitate rigorous supplier verification.

• Generic Competition:
  The expiry of patents for certain formulations fosters price competition, compressing margins.

---

Market Projection and Future Outlook

Forecast for 2023–2030

Considering current growth rates and industry trends, the heparin Sodium 10,000 Units in Sodium Chloride 0.45% segment is expected to maintain a CAGR of approximately 4.5–5.0% over the next seven years. The growth is particularly fueled by emerging markets, expanding indications, and improvements in clinical protocols.

Emerging Opportunities

• Personalized Medicine:
  Dosing algorithms adjusted per patient risk profiles could optimize therapeutic outcomes and reduce adverse events. Clinical trials focusing on pharmacogenomics may drive tailored heparin use.

• New Indications:
  Research exploring the role of heparin in COVID-19-related coagulopathy suggests potential new clinical applications, which could expand market size.

• Enhanced Formulations:
  Biotechnological advances in heparin production—such as recombinant protocols—aim to ensure supply consistency and reduce contamination risks, potentially growing consumer confidence.

Potential Barriers to Growth

Pricing pressures, especially in cost-sensitive regions, and competition from newer oral anticoagulants, such as rivaroxaban and dabigatran, might limit growth. Regulatory modifications aimed at refining safety standards could also temporarily disrupt market supply chains.

---

Conclusion

Heparin Sodium 10,000 Units in Sodium Chloride 0.45% continues to be a cornerstone anticoagulant, with ongoing clinical trials bolstering its safety and efficacy profile. The market remains robust, driven by expanding cardiovascular and surgical procedures globally. While challenges from emerging anticoagulant alternatives and regulatory hurdles persist, technological innovations and targeted therapeutic strategies are poised to sustain its relevance.

---

Key Takeaways

• Clinical pipeline remains active with innovations in delivery systems and dosage management, emphasizing safety.
• The global market is projected to grow steadily at around 5% annually, anchored by rising cardiovascular disease prevalence.
• Emerging markets and COVID-19-related coagulopathy management present new growth avenues.
• Regulatory oversight and safety concerns continue to shape manufacturing and market strategies.
• Competitive pressure from novel anticoagulants necessitates ongoing innovation and patient-centric approaches.

---

FAQs

1. What are the primary clinical indications for Heparin Sodium 10,000 Units in Sodium Chloride 0.45%?
Heparin is chiefly used for prophylaxis and treatment of venous thromboembolism, including DVT and PE, as well as during open-heart surgeries and dialysis procedures to prevent clot formation.

2. Are there any recent advancements in heparin formulations?
Yes. Recent research explores controlled-release patches, liposomal delivery systems, and recombinant manufacturing methods to enhance safety, efficacy, and supply consistency.

3. How is the global market for heparin expected to evolve over the next decade?
The market is expected to grow at approximately 5% annually, driven by increasing cardiovascular disease burden, expanding surgical procedures, and developing economies.

4. What are the major safety concerns associated with heparin use?
Bleeding risks and heparin-induced thrombocytopenia (HIT) remain significant concerns requiring diligent monitoring and patient-specific dosing protocols.

5. How might COVID-19 influence the future use of heparin?
COVID-19-associated coagulopathy has increased interest in heparin for managing clotting complications, potentially expanding its clinical applications.

---

References

[1] Smith J., et al. "Optimized Dosing Strategies for Heparin in Dialysis Patients," Journal of Thrombosis and Haemostasis, 2022.
[2] Lee F., et al. "Liposomal Encapsulation of Heparin for Sustained Release," International Journal of Pharmaceutics, 2021.
[3] Johnson R., et al. "Comparison of Heparin and DOACs in Post-Orthopedic Surgery," Cardiology Today, 2023.
[4] MarketWatch. "Global Heparin Market Forecast 2022–2030," MarketResearch.com, 2022.